Clinical significance of insulin-like growth factor-1 receptor expression in stage I non-small-cell lung cancer: immunohistochemical analysis.
OBJECTIVE
The insulin-like growth factor (IGF) system has been implicated in tumor growth, invasion, and metastasis. However, reports on the IGF-1 receptor (IGF-1R) based on radioimmunoassays are conflicting, and its prognostic implications in non-small-cell lung cancer (NSCLC) are still controversial.


METHODS
Seventy-one paraffin-embedded tissue sections from stage I NSCLC patients were stained using a mouse monoclonal antibody against human IGF-1R.


RESULTS
The intensity and frequency of IGF-1R expression on the membrane and cytoplasm of cancer cells was evaluated and scored using a semiquantitative system. IGF-1R expression was detected in nine of 71 (12.7%) cases. No significant relationship was found between clinical/histopathological parameters and IGF-1R expression. None of the patients whose tumor expressed IGF-1R had experienced distant metastasis or cancer-related death, although the difference did not reach statistical significance.


CONCLUSIONS
We conclude that IGF-1R expression may not be a major prognostic factor for stage I NSCLC.
Lee
Chang Youl
CY
Department of Internal Medicine 1, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon, Korea.
Jeon
Jeong Hee
JH
Kim
Hyung Jung
HJ
Shin
Dong Hwan
DH
Roh
Tae Woong
TW
Ahn
Chul Min
CM
Chang
Yoon Soo
YS
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007334:Insulin-Like Growth Factor I / Q000096:biosynthesis*; D008297:Male; D051379:Mice; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D011379:Prognosis; D017526:Receptor, IGF Type 1 / Q000096:biosynthesis*
D007334:Insulin-Like Growth Factor I; D017526:Receptor, IGF Type 1
Hum Pathol. 1999 Oct;30(10):1128-33
10534157
CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36
11577478
Cancer Res. 1998 Mar 15;58(6):1159-64
9515800
J Endocrinol. 1997 Mar;152(3):339-44
9071953
Cancer Res. 1995 Jan 15;55(2):249-52
7812953
Invest Ophthalmol Vis Sci. 2002 Jan;43(1):1-8
11773005
J Pathol. 1997 Dec;183(4):412-7
9496257
Cancer Res. 1997 Aug 1;57(15):3079-83
9242428
Mol Pathol. 2001 Jun;54(3):125-32
11376122
Lancet Oncol. 2002 May;3(5):298-302
12067807
J Clin Oncol. 1999 Jul;17(7):1983-7
10561248
J Natl Cancer Inst. 2000 Sep 20;92(18):1472-89
10995803
Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12103-8
11035789
Clin Cancer Res. 2005 Jan 1;11(1):206-16
15671548
J Clin Endocrinol Metab. 1996 Oct;81(10):3774-82
8855837
Clin Cancer Res. 2002 Oct;8(10):3259-69
12374697
Clin Cancer Res. 1997 Jan;3(1):103-9
9815544
J Cell Physiol. 2003 Feb;194(2):108-16
12494449
Endocrinology. 2001 Jan;142(1):21-7
11145562
Int J Cancer. 2000 Nov 20;89(6):506-13
11102895
J Biol Chem. 1996 May 10;271(19):11477-83
8626706
Int J Cancer. 2003 Dec 20;107(6):873-7
14601044
Am J Pathol. 1999 Oct;155(4):1271-9
10514409